Nick studied Chemistry at Heidelberg University. During his Bachelor’s thesis in the Cancer Drug Development Group, where he developed covalent, small-molecule KLK6 inhibitors, he discovered his passion for medicinal chemistry and drug discovery. After a research stay at the University of Helsinki in Finland, Nick returned to the lab to concentrate on Targeted Protein Degradation for his Master’s thesis. He then moved to Switzerland to complete an internship in the pharmaceutical research and development department at Roche. In May 2023, Nick joined the Cancer Drug Development Group for his Ph.D., where he is focusing on targeted protein degradation.